Status:
UNKNOWN
Evaluation of Immunological Reconstitution After Haploidentical Bone Marrow Transplantation
Lead Sponsor:
Armando Santoro, MD
Conditions:
Lymphoma
Eligibility:
All Genders
18+ years
Brief Summary
Evaluation of immunological reconstitution after haploidentical BMT using a nonmyeloablative preparative regimen and post-transplant cyclophosphamide in patients with poor prognosis lymphoma
Eligibility Criteria
Inclusion
- Patients with lymphoma (any histology) relapsed after high dose chemotherapy and in partial remission, complete remission or stable disease after the last CT line that
- Signed informed consent to perform an haploidentical allo-BMT using a nonmyeloablative preparative regimen and post-transplant cyclophosphamide
Exclusion
- none
Key Trial Info
Start Date :
January 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2013
Estimated Enrollment :
23 Patients enrolled
Trial Details
Trial ID
NCT01891578
Start Date
January 1 2011
End Date
December 1 2013
Last Update
July 3 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Istituto Clinico Humanitas
Rozzano, MI, Italy, 20089